These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9639551)

  • 1. Role of platelet-activating factor on extravascular lung water after coronary reperfusion in dogs.
    Izuoka T; Takayama Y; Sugiura T; Taniguchi H; Tamura T; Kitashiro S; Jikuhara T; Iwasaka T
    Jpn J Physiol; 1998 Apr; 48(2):157-61. PubMed ID: 9639551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of platelet-activating factor in pulmonary edema after coronary ligation in dogs.
    Taniguchi H; Iwasaka T; Takayama Y; Sugiura T; Inada M
    Chest; 1992 Oct; 102(4):1245-50. PubMed ID: 1395776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of infusion of trieicosapentaenoyl-glycerol emulsion on extravascular lung water during myocardial ischemia and reperfusion in dogs.
    Izuoka T; Kimura Y; Hamazaki T; Tamura T; Kitashiro S; Sugiura T; Jikuhara T; Iwasaka T
    Lipids; 1997 Jan; 32(1):109-14. PubMed ID: 9075200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of platelet activating factor in ischaemia-reperfusion injury of isolated rabbit hearts: protective effect of a specific platelet activating factor antagonist, TCV-309.
    Katoh S; Toyama J; Kodama I; Koike A; Abe T
    Cardiovasc Res; 1993 Aug; 27(8):1430-4. PubMed ID: 8221795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of platelet activating factor in cardiac dysfunction, apoptosis and nitric oxide synthase mRNA expression in the ischemic-reperfused rabbit heart.
    Loucks EB; Godin DV; Walley KR; McManus BM; Rahimian R; Granville DJ; Hong JM; Aktary FM; Qayumi AK
    Can J Cardiol; 2003 Mar; 19(3):267-74. PubMed ID: 12677282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended lung preservation with platelet-activating factor-antagonist TCV-309 in combination with prostaglandin E1.
    Qayumi AK; English JE; Duncan S; Ansley DM; Pearson B; Nikbakht-Sangari M; Sammartino C; Fradet G
    J Heart Lung Transplant; 1997 Sep; 16(9):946-55. PubMed ID: 9322146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of platelet-activating factor in regional myocardial ischemia-reperfusion injury.
    Qayumi AK; English JC; Godin DV; Ansley DM; Loucks EB; Lee JU; Kim CW
    Ann Thorac Surg; 1998 Jun; 65(6):1690-7. PubMed ID: 9647083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of platelet activating factor antagonist (TCV-309) on lung injury in dogs with experimentally endotoxin-induced shock.
    Okano S; Tagawa M; Urakawa N
    J Vet Med Sci; 1995 Aug; 57(4):751-3. PubMed ID: 8519912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of platelet-activating-factor antagonist TCV-309 on arrhythmias and functional recovery during myocardial reperfusion.
    Tamura K; Kimura Y; Tamura T; Kitashiro S; Izuoka T; Tsuji H; Iwasaka T; Inada M
    Coron Artery Dis; 1994 Mar; 5(3):267-73. PubMed ID: 8199742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor administration of PAF antagonist (TCV-309) enhances lung preservation.
    Ide S; Kawahara K; Takahashi T; Sasaki N; Shingu H; Nagayasu T; Yamamoto S; Tagawa T; Tomita M
    Transplant Proc; 1995 Feb; 27(1):570-3. PubMed ID: 7879103
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic potential of platelet-activating factor antagonism in the management of myocardial infarction.
    Loucks EB; Qayumi AK; Godin DV; English JC; Lim SP; Al Mahmeed T; Gul S
    Can J Cardiol; 2000 Apr; 16(4):497-504. PubMed ID: 10787465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological profile of TCV-309--a potent PAF antagonist.
    Terashita Z; Takatani M; Nishikawa K
    J Lipid Mediat; 1992; 5(2):183-5. PubMed ID: 1445598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary edema formation after myocardial infarction and coronary reperfusion: intravascular and extravascular pulmonary fluid volumes. IV.
    Slutsky RA; Mattrey RF
    Circ Shock; 1984; 13(2):183-91. PubMed ID: 6744522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet-activating factor antagonist (TCV-309) attenuates the priming effects of bronchoalveolar macrophages in cerulein-induced pancreatitis rats.
    Yamaguchi Y; Matsumura F; Liang J; Okabe K; Matsuda T; Ohshiro H; Ishihara K; Akizuki E; Yamada S; Ogawa M
    Pancreas; 1999 May; 18(4):355-63. PubMed ID: 10231840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet-activating factor in hepatic ischemia/reperfusion injury. The effects of a PAF antagonist combined with a prostaglandin I2 analogue.
    Nishiyama R; Nakamura S; Suzuki S; Baba S
    Transplantation; 1993 Jun; 55(6):1261-5. PubMed ID: 8516812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The roles of platelet-activating factor and endothelin-1 in renal damage after total hepatic ischemia and reperfusion.
    Suzuki S; Serizawa A; Sakaguchi T; Tsuchiya Y; Kojima Y; Okamoto K; Kurachi K; Konno H; Fujise Y; Baba S; Nakamura S
    Transplantation; 2000 Jun; 69(11):2267-73. PubMed ID: 10868624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TCV-309, a novel platelet activating factor antagonist, inhibits leukocyte accumulation and protects against splanchnic artery occlusion shock.
    Canale P; Squadrito F; Altavilla D; Ioculano M; Zingarelli B; Campo GM; Urna G; Sardella A; Squadrito G; Caputi AP
    Agents Actions; 1994 Oct; 42(3-4):128-34. PubMed ID: 7879698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet activating factor causes hyperconstriction at the inflammatory coronary lesions in pigs in vivo.
    Kozai T; Shimokawa H; Yamawaki T; Fukumoto Y; Kadokami T; Kuwata K; Katsumata N; Egashira K; Takeshita A
    Coron Artery Dis; 1997 Jul; 8(7):423-32. PubMed ID: 9383603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of nitric oxide and eicosanoids in platelet-activating factor-induced haemodynamic and haematological effects in dogs.
    Noguchi K; Matsuzaki T; Shiroma N; Ojiri Y; Sakanashi M
    Br J Pharmacol; 1996 Jun; 118(4):941-50. PubMed ID: 8799566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of TCV-309, a novel PAF antagonist, on circulatory shock and hematological abnormality induced by endotoxin in dogs.
    Kawamura M; Kitayoshi T; Terashita Z; Fujiwara S; Takatani M; Nishikawa K
    J Lipid Mediat Cell Signal; 1994 May; 9(3):255-65. PubMed ID: 7921785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.